Nasu H, Hibi N, Ohyashiki J H, Hara A, Kubono K, Tsukada Y, Ando K, Iwama H, Hayashi S, Yahata N, Toyama K, Ohyashiki K
SRL, Inc., Hachioji, Tokyo 192, Japan.
Int J Oncol. 1998 Sep;13(3):525-30. doi: 10.3892/ijo.13.3.525.
To determine the clinical implications of soluble CD44 (sCD44) levels in hematologic neoplasias, we developed an enzyme-linked immunosorbent assay for sCD44 using two monoclonal antibodies to the standard 90 kDa form, and assessed the serum concentration of sCD44 in normal healthy volunteers, patients with acute leukemia, myelodysplastic syndromes (MDS), and those with chronic myeloid leukemia (CML). Compared to that in normal individuals (n=51; 145. 1 24.6 ng/ml), the serum sCD44 level was significantly elevated in patients with acute myeloid leukemia (AML; n=18; 331.9 99.0 ng/ml, P=0.0001), acute lymphoid leukemia (ALL; n=16; 551.3 427.8 ng/ml, P=0.0001) and CML (n=18; 262.0 97.5 ng/ml, P=0.0001). The sCD44 level was slightly elevated in patients with MDS (n=43; 173.8 54.9 ng/ml, P=0.0071). In patients with acute leukemia, serum sCD44 concentrations decreased significantly in response to treatment and reached nearly normal levels after complete remission (P=0.0005 in AML and P=0.0032 in ALL). The sCD44 levels in patients with MDS increased after they developed acute leukemia, whereas no significant difference in sCD44 levels was observed between the chronic and the blastic phases in patients with CML. Our results indicate that serum sCD44 levels may be a useful marker for monitoring response to treatment and disease progression, especially in acute leukemia.
为了确定可溶性CD44（sCD44）水平在血液系统肿瘤中的临床意义，我们使用两种针对标准90 kDa形式的单克隆抗体开发了一种sCD44酶联免疫吸附测定法，并评估了正常健康志愿者、急性白血病患者、骨髓增生异常综合征（MDS）患者以及慢性髓性白血病（CML）患者血清中sCD44的浓度。与正常个体（n = 51；145.1±24.6 ng/ml）相比，急性髓性白血病（AML；n = 18；331.9±99.0 ng/ml，P = 0.0001）、急性淋巴细胞白血病（ALL；n = 16；551.3±427.8 ng/ml，P = 0.0001）和CML（n = 18；262.0±97.5 ng/ml，P = 0.0001）患者的血清sCD44水平显著升高。MDS患者（n = 43；173.8±54.9 ng/ml，P = 0.0071）的sCD44水平略有升高。在急性白血病患者中，血清sCD44浓度在治疗后显著下降，并在完全缓解后达到接近正常水平（AML中P = 0.0005，ALL中P = 0.0032）。MDS患者发生急性白血病后sCD44水平升高，而CML患者慢性期和急变期的sCD44水平无显著差异。我们的结果表明，血清sCD44水平可能是监测治疗反应和疾病进展的有用标志物，尤其是在急性白血病中。
